Verici Dx Plc (VRCI)

Currency in GBP
0.53
0.00(0.00%)
Real-time Data·
VRCI Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week Low
VRCI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.470.60
52 wk Range
0.477.70
Key Statistics
Bid/Ask
0.50 / 0.55
Prev. Close
0.53
Open
0.53
Day's Range
0.47-0.6
52 wk Range
0.47-7.7
Volume
-
Average Volume (3m)
990.82K
1-Year Change
-93.16%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VRCI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Verici Dx Plc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Verici Dx Plc Company Profile

Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. It also offers sequencing services for tumor-only, tumor-normal, and germline exomes; whole transcriptome, targeted RNASeq and ncRNAs, and functional binding multicell assay. In addition, the company provides bioinformatics and data science services for exome analysis options; RNA pipeline; multiomic signature discovery, TCR clonotype antigen identification, custom pipeline building, and predictive modeling; and simulation of 100s of drug combinations against multiomic personalized tumor models. It has collaborations with One Lambda Inc. for the commercialization of pre transplant risk assessment (PTRA), a pre-transplant prognosis test for the risk of early acute rejection; The Westmead Institute for Medical Research to determine the factors contributing to graft loss in organ transplants; and FBB Biomed, Inc., which provides research-use-only tests for clinicians seeking insights into neurologic diseases, such as multiple sclerosis and long COVID. Verici Dx plc was incorporated in 2020 and is based in Cardiff, the United Kingdom.

Compare VRCI to Peers and Sector

Metrics to compare
VRCI
Peers
Sector
Relationship
P/E Ratio
−1.8x−3.2x−0.5x
PEG Ratio
−0.04−0.100.00
Price/Book
2.0x2.8x2.6x
Price / LTM Sales
3.2x9.6x3.3x
Upside (Analyst Target)
-187.6%43.5%
Fair Value Upside
Unlock21.8%6.9%Unlock

Earnings

Latest Release
Jun 30, 2025
EPS / Forecast
-0.02 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

VRCI Income Statement

FAQ

What Stock Exchange Does Verici Trade On?

Verici is listed and trades on the London Stock Exchange stock exchange.

What Is the Stock Symbol for Verici?

The stock symbol for Verici is "VRCI."

What Is the Verici Market Cap?

As of today, Verici market cap is 7.95M.

What Is Verici's Earnings Per Share (TTM)?

The Verici EPS (TTM) is -0.03.

From a Technical Analysis Perspective, Is VRCI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Verici Stock Split?

Verici has split 0 times.

How Many Employees Does Verici Have?

Verici has 18 employees.

What is the current trading status of Verici (VRCI)?

As of 07 Aug 2025, Verici (VRCI) is trading at a price of 0.53, with a previous close of 0.53. The stock has fluctuated within a day range of 0.47 to 0.60, while its 52-week range spans from 0.47 to 7.70.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.